Raymond James Financial Inc. Takes $1.03 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Raymond James Financial Inc. acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 54,453 shares of the company's stock, valued at approximately $1,026,000. Raymond James Financial Inc. owned 0.07% of Nurix Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the company. US Bancorp DE raised its holdings in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock worth $27,000 after purchasing an additional 842 shares during the period. Quarry LP increased its position in shares of Nurix Therapeutics by 3,746.2% in the third quarter. Quarry LP now owns 2,500 shares of the company's stock valued at $56,000 after buying an additional 2,435 shares in the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Nurix Therapeutics during the 3rd quarter worth approximately $240,000. China Universal Asset Management Co. Ltd. lifted its holdings in Nurix Therapeutics by 21.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company's stock valued at $283,000 after purchasing an additional 2,632 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Nurix Therapeutics in the third quarter valued at about $346,000.

Insider Buying and Selling

In related news, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Houte Hans Van sold 5,825 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the sale, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at approximately $488,660.76. This trade represents a 14.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,326 shares of company stock valued at $213,449. 9.80% of the stock is currently owned by company insiders.

Nurix Therapeutics Stock Performance

NASDAQ NRIX traded down $0.46 during trading hours on Tuesday, hitting $9.26. 1,051,354 shares of the company's stock were exchanged, compared to its average volume of 916,911. The business's 50 day moving average is $14.83 and its 200-day moving average is $19.56. Nurix Therapeutics, Inc. has a 12-month low of $8.60 and a 12-month high of $29.56. The firm has a market capitalization of $705.95 million, a P/E ratio of -3.20 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Wednesday, April 9th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the prior year, the business earned ($0.76) earnings per share. As a group, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NRIX. Stifel Nicolaus raised their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Leerink Partners began coverage on shares of Nurix Therapeutics in a research note on Monday, March 17th. They issued a "market perform" rating and a $16.00 price objective for the company. BTIG Research initiated coverage on Nurix Therapeutics in a research report on Tuesday, December 10th. They set a "buy" rating and a $35.00 target price on the stock. Leerink Partnrs raised Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. Finally, Stephens reissued an "overweight" rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $30.88.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.